594 related articles for article (PubMed ID: 23551700)
1. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
[TBL] [Abstract][Full Text] [Related]
2. The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature.
Swietek N; Waldert M; Rom M; Schatzl G; Wiener HG; Susani M; Klatte T
J Urol; 2012 Sep; 188(3):748-53. PubMed ID: 22819422
[TBL] [Abstract][Full Text] [Related]
3. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
[TBL] [Abstract][Full Text] [Related]
4. Discrepancies between cytology, cystoscopy and biopsy in bladder cancer detection after Bacille Calmette-Guerin intravesical therapy.
Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
Int J Urol; 2009 Feb; 16(2):192-5. PubMed ID: 19054166
[TBL] [Abstract][Full Text] [Related]
5. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
6. Can random bladder biopsies be eliminated after bacillus Calmette-Guérin therapy against carcinoma in situ?
Takamatsu K; Matsumoto K; Kikuchi E; Ogihara K; Hayakawa N; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Asanuma H; Mikami S; Oyama M; Oya M
Int Urol Nephrol; 2021 Mar; 53(3):465-469. PubMed ID: 33025406
[TBL] [Abstract][Full Text] [Related]
7. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
Holmäng S; Ströck V
Eur Urol; 2012 Mar; 61(3):503-7. PubMed ID: 22119022
[TBL] [Abstract][Full Text] [Related]
8. Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer.
Lightfoot AJ; Rosevear HM; Nepple KG; O'Donnell MA
Int J Urol; 2012 Nov; 19(11):988-93. PubMed ID: 22762480
[TBL] [Abstract][Full Text] [Related]
9. Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?
Calò B; Sanguedolce F; Falagario UG; Chirico M; Fortunato F; Carvalho-Diaz E; Busetto GM; Bettocchi C; Carrieri G; Cormio L
World J Urol; 2021 Oct; 39(10):3815-3821. PubMed ID: 33830306
[TBL] [Abstract][Full Text] [Related]
10. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.
Nurminen P; Ettala O; Seppänen M; Taimen P; Boström PJ; Kaipia A
BJU Int; 2019 Feb; 123(2):246-251. PubMed ID: 29959824
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
12. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
13. Commentary on "The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature." Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, Klatte T. Department of Urology, Medical University of Vienna, Vienna, Austria: J Urol 2012;188(3):748-53 [Epub 2012 Jul 20].
See WA
Urol Oncol; 2013 Jul; 31(5):715-6. PubMed ID: 23796199
[TBL] [Abstract][Full Text] [Related]
14. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin treatment of 39 patients with superficial transitional cell carcinoma of the bladder.
al Khalifa MA; Elfving P; Månsson W; Colleen S
Scand J Urol Nephrol; 1991; 25(2):135-9. PubMed ID: 1871559
[TBL] [Abstract][Full Text] [Related]
16. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Ray ER; Chatterton K; Khan MS; Chandra A; Thomas K; Dasgupta P; O'Brien TS
BJU Int; 2010 Mar; 105(6):789-94. PubMed ID: 19832725
[TBL] [Abstract][Full Text] [Related]
17. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
18. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
20. Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus calmette-guerin therapy.
Murakami T; Ebara S; Saika T; Irie S; Takeda K; Maki Y; Miyaji S; Manabe D; Kaku H; Nasu Y; Tsushima T; Kumon H
Acta Med Okayama; 2007 Dec; 61(6):341-4. PubMed ID: 18183079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
